We are an innovative R&D platform based on quantum physics, powered by artificial intelligence, and driven by robots. We use a combination of first-principles computation based on quantum physics1, artificial intelligence, high-performance cloud computing, and scalable and standardized robotic automation to provide pharmaceutical and material science R&D solutions and services to global and domestic companies in the pharmaceutical and material science industries (including agricultural technology, energy, new chemicals, and cosmetics). We have a diverse customer base, ranging from startups to global biotech and pharmaceutical companies and unicorns and leading companies in the field of new materials. According to Frost & Sullivan, our customer base includes 16 of the top 20 global biotech and pharmaceutical companies (by 2022 revenue), which we consider to be an indicator of our solutions and service levels. By operating in both China and the US, we strive to meet the changing needs of our customers, collaborators, and academic partners by leveraging the best capabilities and resources available in each region. We have established long-term and stable cooperative relationships with many of the world's leading biotechnology and pharmaceutical enterprise groups and leading companies in the field of new materials, such as Pfizer, Johnson & Johnson, Germany's Darmstadt Merck Group, and GCL Group, and most of them are our repeat customers. Since our establishment, we have received strong investment and support from world-renowned private equity investors and strategic investors, including Sequoia China, Future Assets, Google, Tencent, China Life Insurance Chengda, and Wuyuan Capital. We believe our blue-chip shareholder base and outstanding customer base are proof of our capabilities and prospects. visions Our vision is to become a global leader in pharmaceutical and materials science research and development enabled by quantum physics and artificial intelligence. mission Our mission is a world where technology is smarter and life is better. We aim to accelerate the design and discovery of novel drugs and materials using quantum physics2, artificial intelligence, and robotic automation.